PMID- 31808397
OWN - NLM
STAT- MEDLINE
DCOM- 20200122
LR  - 20200804
IS  - 1677-6119 (Electronic)
IS  - 1677-5538 (Print)
IS  - 1677-5538 (Linking)
VI  - 45
IP  - 6
DP  - 2019 Nov-Dec
TI  - Intensity modulated radiotherapy (IMRT) or conformational radiotherapy (3D-CRT) 
      with conventional fractionation for prostate cancer: Is there any clinical 
      difference?
PG  - 1105-1112
LID - 10.1590/S1677-5538.IBJU.2018.0842 [doi]
AB  - PURPOSE: To compare the treatment outcomes of a cohort of prostate cancer 
      patients treated with conventional schedule using IMRT or 3DRT technique. 
      MATERIALS AND METHODS: Between 2010-2017, 485 men with localized prostate cancer 
      were treated with conventional radiotherapy schedule with a total dose >/=74Gy 
      using IMRT (231) or 3DCRT (254). Late gastrointestinal (GI) and genitourinary 
      (GU) toxicity were retrospectively evaluated according to modifi ed RTOG 
      criteria. The biochemical control was defi ned by the Phoenix criteria (nadir + 
      2ng/mL). The comparison between the groups included biochemical recurrence free 
      survival (bRFS), overall survival (OS) and late toxicity. RESULTS: With a median 
      follow-up of 51 months (IMRT=49 and 3DRT=51 months), the maximal late GU for >/= 
      grade- 2 during the entire period of follow-up was 13.1% in the IMRT and 15.4% in 
      the 3DRT (p=0.85). The maximal late GI >/= grade- 2 in the IMRT was 10% and in the 
      3DRT 24% (p=0.0001). The 5-year bRFS for all risk groups with IMRT and 3D-CRT was 
      87.5% vs. 87.2% (p=0.415). Considering the risk-groups no signifi cant difference 
      for low-, intermediate- and high-risk groups between IMRT (low-95.3%, 
      intermediate-86.2% and high-73%) and 3D-CRT (low-96.4%, intermediate-88.2% and 
      high-76.6%, p=0.448) was observed. No signifi cant differences for OS and DMFS 
      were observed comparing treatment groups. CONCLUSION: IMRT reduces signifi cantly 
      the risk of late GI severe complication compared with 3D-CRT using conventional 
      fractionation with a total dose >/=74Gy without any differences for bRFS and OS.
CI  - Copyright(R) by the International Brazilian Journal of Urology.
FAU - Viani, Gustavo
AU  - Viani G
AD  - Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo - USP, 
      Ribeirao Preto, SP, Brasil.
FAU - Hamamura, Ana Carolina
AU  - Hamamura AC
AD  - Departamento de Radioterapia, Faculdade de Medicina de Ribeirao Preto, 
      Universidade de Sao Paulo, Ribeirao Preto, SP, Brasil.
FAU - Faustino, Alexandre C
AU  - Faustino AC
AD  - Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo - USP, 
      Ribeirao Preto, SP, Brasil.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Brazil
TA  - Int Braz J Urol
JT  - International braz j urol : official journal of the Brazilian Society of Urology
JID - 101158091
SB  - IM
MH  - Aged
MH  - Disease-Free Survival
MH  - Dose-Response Relationship, Radiation
MH  - Gastrointestinal Tract/radiation effects
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Prostatic Neoplasms/mortality/pathology/*radiotherapy
MH  - Radiation Injuries
MH  - Radiotherapy Dosage
MH  - Radiotherapy, Conformal/adverse effects/*methods
MH  - Radiotherapy, Intensity-Modulated/adverse effects/*methods
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Urogenital System/radiation effects
PMC - PMC6909869
OTO - NOTNLM
OT  - Prostatic Neoplasms
OT  - Radiotherapy, Conformal
OT  - Toxicity [Subheading]
COIS- None declared.
EDAT- 2019/12/07 06:00
MHDA- 2020/01/23 06:00
PMCR- 2019/12/17
CRDT- 2019/12/07 06:00
PHST- 2019/01/23 00:00 [received]
PHST- 2019/05/01 00:00 [accepted]
PHST- 2019/12/07 06:00 [entrez]
PHST- 2019/12/07 06:00 [pubmed]
PHST- 2020/01/23 06:00 [medline]
PHST- 2019/12/17 00:00 [pmc-release]
AID - IBJU20180842 [pii]
AID - S1677-5538.IBJU.2018.0842 [pii]
AID - 10.1590/S1677-5538.IBJU.2018.0842 [doi]
PST - ppublish
SO  - Int Braz J Urol. 2019 Nov-Dec;45(6):1105-1112. doi: 
      10.1590/S1677-5538.IBJU.2018.0842.